Corindus Vascular Robotics’ CorPath system will be highlighted in several presentations on new therapies and techniques for the treatment of high-risk patients with complex cardiovascular disease at the San Diego Cardiovascular Interventions Course (SDCI; 8–9 July, San Diego, USA). The system is the first FDA-cleared medical device to bring robotically-assisted precision to radial, coronary and peripheral procedures.
A press release reports that the SDCI 2016 course will highlight how robotic therapy can enhance physician and staff safety when used in complex and high-risk PCI procedures. A particular focus will be the integration of robotic therapy in procedures that also leverage the capabilities of other advanced therapeutic tools.
SDCI course director Ehtisham Mahmud (Cardiovascular Medicine and Medical Director, Sulpizio Cardiovascular Center at the University of California, USA), says: “Robotic therapy has transformed the way we perform interventional procedures today. The benefits of robotics for staff and patients will continue to grow as technology evolves, and we are excited to be at the forefront of this growth. This course seeks to highlight the value and applicability of robotic therapy in conjunction with other emerging technologies in the cath lab to treat complex disease.”